Which instruction would the nurse provide to a patient who is receiving anticoagulant therapy?

1. How-to Guide: Prevent Harm from High-Alert Medications. Institute for Healthcare Improvement; Cambridge, MA, USA: 2012. [(accessed on 29 March 2018)]. Available online: http://www.ismp.org/Tools/highalertmedications.pdf [Google Scholar]

2. Piazza G., Nguyen T.N., Cios D., Labreche M., Hohlfelder B., Fanikos J., Fiumara K., Goldhaber S.Z. Anticoagulation-associated adverse drug events. Am. J. Med. 2011;124:1136–1142. doi: 10.1016/j.amjmed.2011.06.009. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. The Joint Commission National Patient Safety Goals 2018. [(accessed on 19 April 2018)]; Available online: https://www.jointcommission.org/assets/1/6/NPSG_Chapter_HAP_Jan2018.pdf

4. Garcia D.A., Witt D.M., Hylek E., Wittkowsky A.K., Nutescu E.A., Jacobson A., Moll S., Merli G.J., Crowther M., Earl L., et al. Delivery of optimized anticoagulant therapy: Consensus statement from the Anticoagulation Forum. Ann. Pharmacother. 2008;42:979–988. doi: 10.1345/aph.1L098. [PubMed] [CrossRef] [Google Scholar]

5. Saokaew S., Permsuwan U., Chaiyakunapruk N., Nathisuwan S., Sukonthasarn A. Effectiveness of pharmacist-participated warfarin therapy management: A systematic review and metaanalysis. J. Thromb. Haemost. 2010;8:2418–2427. doi: 10.1111/j.1538-7836.2010.04051.x. [PubMed] [CrossRef] [Google Scholar]

6. Bishop M.A., Streiff M.B., Ensor C.R., Tedford R.J., Russell S.D., Ross P.A. Pharmacist-managed international normalized ratio patient self-testing is associated with increased time in therapeutic range in patients with left ventricular assist devices at an academic medical center. ASAIO J. 2014;60:193–198. doi: 10.1097/MAT.0000000000000047. [PubMed] [CrossRef] [Google Scholar]

7. Bungard T.J., Gardner L., Archer S.L., Hamilton P., Ritchie B., Tymchak W., Tsuyuki R.T. Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med. 2009;3:e16–e21. [PMC free article] [PubMed] [Google Scholar]

8. Challen L., Agbahiwe S., Cantieri T., Olivetti J.G., Mbah T., Mendoza-Becerra Y., Munoz C., Nguyen M., Partee K., Lal L., et al. Impact of Point-of-Care Implementation in Pharmacist-Run Anticoagulation Clinics within a Community-Owned Health System: A Two-Year Retrospective Analysis. Hosp. Pharm. 2015;50:783–788. doi: 10.1310/hpj5009-783. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Chilipko A.A., Norwood D.K. Evaluating warfarin management by pharmacists in a community teaching hospital. Consult. Pharm. 2014;29:95–103. doi: 10.4140/TCP.n.2014.95. [PubMed] [CrossRef] [Google Scholar]

10. Garton L., Crosby J.F. A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability. J. Thromb. Thrombolysis. 2011;32:426–430. doi: 10.1007/s11239-011-0612-7. [PubMed] [CrossRef] [Google Scholar]

11. Holden J., Holden K. Comparative effectiveness of general practitioner versus pharmacist dosing of patients requiring anticoagulation in the community. J. Clin. Pharm. Ther. 2000;25:49–54. doi: 10.1046/j.1365-2710.2000.00262.x. [PubMed] [CrossRef] [Google Scholar]

12. Young S., Bishop L., Twells L., Dillon C., Hawboldt J., O’Shea P. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam. Pract. 2011;12:88. doi: 10.1186/1471-2296-12-88. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Ingram S.J., Kirkdale C.L., Williams S., Hartley E., Wintle S., Sefton V., Thornley T. Moving anticoagulation initiation and monitoring services into the community: Evaluation of the Brighton and hove community pharmacy service. BMC Health Serv. Res. 2018;18:91. doi: 10.1186/s12913-018-2901-8. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Harrison J., Shaw J.P., Harrison J.E. Anticoagulation management by community pharmacists in New Zealand: An evaluation of a collaborative model in primary care. Int. J. Pharm. Pract. 2015;23:173–181. doi: 10.1111/ijpp.12148. [PubMed] [CrossRef] [Google Scholar]

15. Locke C., Ravnan S.L., Patel R., Uchizono J.A. Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy. 2005;25:685–689. doi: 10.1592/phco.25.5.685.63582. [PubMed] [CrossRef] [Google Scholar]

16. Rudd K.M., Dier J.G. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy. 2010;30:330–338. doi: 10.1592/phco.30.4.330. [PubMed] [CrossRef] [Google Scholar]

17. Holbrook A., Schulman S., Witt D.M., Vandvik P.O., Fish J., Kovacs M.J., Svensson P.J., Veenstra D.L., Crowther M., Guyatt G.H. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl. 2):e152S–e184S. doi: 10.1378/chest.11-2295. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Wittkowsky A.K. Impact of target-specific oral anticoagulants on transitions of care and outpatient care models. J. Thromb. Thrombolysis. 2013;35:304–311. doi: 10.1007/s11239-013-0879-y. [PubMed] [CrossRef] [Google Scholar]

19. Zdyb E.G., Courtney D.M., Malik S., Schmidt M.J., Lyden A.E. Impact of Discharge Anticoagulation Education by Emergency Department Pharmacists at a Tertiary Academic Medical Center. J. Emerg. Med. 2017;53:896–903. doi: 10.1016/j.jemermed.2017.06.008. [PubMed] [CrossRef] [Google Scholar]

20. Dharmarajan T.S., Gupta A., Baig M.A., Norkus E.P. Warfarin: Implementing its safe use in hospitalized patients from nursing homes and community through a performance improvement initiative. J. Am. Med. Dir. Assoc. 2011;12:518–523. doi: 10.1016/j.jamda.2010.04.007. [PubMed] [CrossRef] [Google Scholar]

21. Wang Y., Kong M.C., Lee L.H., Ng H.J., Ko Y. Knowledge, satisfaction, and concerns regarding warfarin therapy and their association with warfarin adherence and anticoagulation control. Thromb. Res. 2014;133:550–554. doi: 10.1016/j.thromres.2014.01.002. [PubMed] [CrossRef] [Google Scholar]

22. Manzoor B.S., Lee T.A., Sharp L.K., Walton S.M., Galanter W.L., Nutescu E.A. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy. 2017;37:1221–1230. doi: 10.1002/phar.1989. [PubMed] [CrossRef] [Google Scholar]

23. Heidbuchel H., Verhamme P., Alings M., Antz M., Hacke W., Oldgren J., Sinnaeve P., Camm A.J., Kirchhof P. European Heart Rhythm Association. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15:625–651. doi: 10.1093/europace/eut083. [PubMed] [CrossRef] [Google Scholar]

24. Burnett A.E., Mahan C.E., Vazquez S.R., Oertel L.B., Garcia D.A., Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTEtreatment. J. Thromb. Thrombolysis. 2016;41:206–232. doi: 10.1007/s11239-015-1310-7. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Simon J., Hawes E., Deyo Z., Bryant Shilliday B. Evaluation of prescribing and patient use of target-specific oral anticoagulants in the outpatient setting. J. Clin. Pharm. Ther. 2015 doi: 10.1111/jcpt.12296. [PubMed] [CrossRef] [Google Scholar]

26. Howard M., Lipshutz A., Roess B., Hawes E., Deyo Z., Burkhart J., Moll S., Shilliday B. Identification of Risk Factors for Inappropriate and Suboptimal Initiation of Direct Oral Anticoagulants. J. Thromb. Thrombolysis. 2017;43:149–156. doi: 10.1007/s11239-016-1435-3. [PubMed] [CrossRef] [Google Scholar]

27. Eliquis [package insert] Bristol-Myers Squibb Company; Princeton, NJ, USA: 2012. [Google Scholar]

28. Pradaxa [package insert] Boehringer Ingelheim Pharmaceuticals Inc.; Ridgefield, CT, USA: 2010. [Google Scholar]

29. Xarelto [package insert] Janssen Pharmaceuticals, Inc.; Titusville, NJ, USA: 2011. [Google Scholar]

30. Savaysa [package insert] Daiichi Sankyo, Inc.; Basking Ridge, NJ, USA: 2017. [Google Scholar]

31. Chan L.L., Crumpler W.L., Jacobson A.K. Implementation of pharmacist-managed anticoagulation in patients receiving newer anticoagulants. Am. J. Health Syst. Pharm. 2013;70:1285–1286, 1288. doi: 10.2146/ajhp120468. [PubMed] [CrossRef] [Google Scholar]

32. Lane D.A., Aguinaga L., Blomström-Lundqvist C., Boriani G., Dan G.A., Hills M.T., Hylek E.M., LaHaye S.A., Lip G.Y., Lobban T., et al. Cardiac tachyarrhythmias and patient values and preferences for their management: The European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE) Europace. 2015;17:1747–1769. doi: 10.1093/europace/euv233. [PubMed] [CrossRef] [Google Scholar]

33. James J. Patient engagement. Health Affairs 2013. [(accessed on 28 January 2018)]; Available online: http://www.healthaffairs.org/healthpolicybriefs/brief.php?brief_id=86

34. Hibbard J.H., Greene J., Overton V. Patients with lower activation associated with higher costs; delivery systems should know their patients’ ‘‘Scores’’ Health Aff. 2013;32:216–222. doi: 10.1377/hlthaff.2012.1064. [PubMed] [CrossRef] [Google Scholar]

35. Institute of Medicine . Committee on Identifying and Preventing Medication Errors. Preventing Medication Errors. The National Academies Press; Washington, DC, USA: 2006. [Google Scholar]

36. American Society of Health-System Pharmacy ASHP Guidelines on Pharmacist-Conducted Patient Education and Counseling. [(accessed on 29 March 2018)]; Available online: https://www.ashp.org/DocLibrary/BestPractices/OrgGdlPtEduc.aspx

37. American Society of Hospital Pharmacists ASHP statement on pharmaceutical care. [(accessed on 29 March 2018)];Am. J. Hosp. Pharm. 1993 50:1720–1723. Available online: http://www.ashp.org/doclibrary/bestpractices/orgstpharmcare.aspx [Google Scholar]

38. Johnson A., Sandford J., Tyndall J. Written and verbal information versus verbal information only for patients being discharged from acute hospital settings to home. Cochrane Database Syst. Rev. 2003 doi: 10.1002/14651858.CD003716. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Institute for Safe Medication Practices (ISMP) [(accessed on 28 January 2018)];2003 Available online: https://www.ismp.org/Survey/surveyresults/NursingSurvey.asp

40. Health Literacy in Pharmacy. Agency for Healthcare Research and Quality; Rockville, MD, USA: [(accessed on 29 March 2018)]. Available online: http://www.ahrq.gov/professionals/education/curriculum-tools/pharmlitqi/ppt-slides.html [Google Scholar]

41. Davis T.C., Wolf M.S., Bass P.F., III, Thompson J.A., Tilson H.H., Neuberger M., Parker R.M. Literacy and misunderstanding prescription drug labels. Ann. Intern. Med. 2006;145:887–894. doi: 10.7326/0003-4819-145-12-200612190-00144. [PubMed] [CrossRef] [Google Scholar]

42. Hernández Madrid A., Potpara T.S., Dagres N., Chen J., Larsen T.B., Estner H., Todd D., Bongiorni M.G., Sciaraffiam E., Proclemerm A., et al. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: Result of a self-assessment patient survey conducted by the European Heart Rhythm Association. Europace. 2016;18:463–467. doi: 10.1093/europace/euv448. [PubMed] [CrossRef] [Google Scholar]

43. Anticoagulation Toolkit: Reducing Adverse Drug Events & Potential Adverse Drug Events with Unfractionated Heparin, Low Molecular Weight Heparins and Warfarin. [(accessed on 17 January 2018)]; Available online: http://excellence.acforum.org/sites/default/files/Purdue%20Univ%20Anticoag%20Toolkit.pdf

44. Moreland C.J., Kravitz R.L., Paterniti D.A., Li C.S., Lin T.C., White R.H. Anticoagulation education: Do patients understand potential medication-related emergencies? Jt. Comm. J. Qual. Patient Saf. 2013;39:22–31. doi: 10.1016/S1553-7250(13)39005-9. [PubMed] [CrossRef] [Google Scholar]

45. Witt D.M., Clark N.P., Kaatz S., Schnurr T., Ansell J.E. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J. Thromb. Thrombolysis. 2016;41:187–205. doi: 10.1007/s11239-015-1319-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]